SAN

81.87

-1.87%↓

MRK1

117.8

+0.04%↑

SHL.DE

44.51

+1.16%↑

ARGX

700.8

-6.83%↓

FRE

48.26

+1.05%↑

SAN

81.87

-1.87%↓

MRK1

117.8

+0.04%↑

SHL.DE

44.51

+1.16%↑

ARGX

700.8

-6.83%↓

FRE

48.26

+1.05%↑

SAN

81.87

-1.87%↓

MRK1

117.8

+0.04%↑

SHL.DE

44.51

+1.16%↑

ARGX

700.8

-6.83%↓

FRE

48.26

+1.05%↑

SAN

81.87

-1.87%↓

MRK1

117.8

+0.04%↑

SHL.DE

44.51

+1.16%↑

ARGX

700.8

-6.83%↓

FRE

48.26

+1.05%↑

SAN

81.87

-1.87%↓

MRK1

117.8

+0.04%↑

SHL.DE

44.51

+1.16%↑

ARGX

700.8

-6.83%↓

FRE

48.26

+1.05%↑

Inicio・Lista de Acciones・Pharming Group NV

P
Pharming Group NV

Abierto

1.431 -2.32

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.43

Máximo

1.465

Métricas clave
By Trading Economics
Ingresos	2.9M 7.5M
Ventas	4.1M 97M
BPA	0.009
Margen de beneficios	7.758
Empleados	404

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	685K 998M
Apertura anterior	3.75
Cierre anterior	1.431

Pharming Group NV Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

14 dic 2025, 22:53 UTC

Adquisiciones, fusiones, absorciones

Fortescue to Take Full Control of US$101 Million Copper Miner Alta

13 dic 2025, 00:04 UTC

Adquisiciones, fusiones, absorciones

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6 Billion, Bloomberg Reports, Citing Sources

14 dic 2025, 23:46 UTC

Charlas de Mercado

Gold Edges Higher Amid Some Tailwinds -- Market Talk

14 dic 2025, 23:36 UTC

Charlas de Mercado

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

14 dic 2025, 22:38 UTC

Adquisiciones, fusiones, absorciones

Fortescue to Take Full Control of US$101M Copper Miner Alta

14 dic 2025, 22:02 UTC

Adquisiciones, fusiones, absorciones

Fortescue: Transaction Is Consistent With Critical Minerals Strategy

14 dic 2025, 22:01 UTC

Adquisiciones, fusiones, absorciones

Fortescue: Alta Owns the Canariaco Project in Northern Peru

14 dic 2025, 22:01 UTC

Adquisiciones, fusiones, absorciones

Fortescue: Alta Directors Unanimously Recommend Proposal, Will Vote in Favor

14 dic 2025, 22:00 UTC

Adquisiciones, fusiones, absorciones

Fortescue: Agreement Implies Total Equity Value of C$139 Million

14 dic 2025, 22:00 UTC

Adquisiciones, fusiones, absorciones

Fortescue to Pay C$1.40/Share for Securities It Does Not Already Own

14 dic 2025, 21:59 UTC

Adquisiciones, fusiones, absorciones

Fortescue to Acquire Remaining 64% of Alta Copper

14 dic 2025, 17:00 UTC

Ganancias

Tonka Trucks Gambled on Keeping Production in China and Survived -- Barely -- WSJ

14 dic 2025, 08:30 UTC

Adquisiciones, fusiones, absorciones

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

13 dic 2025, 16:48 UTC

Adquisiciones, fusiones, absorciones

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13 dic 2025, 08:00 UTC

Adquisiciones, fusiones, absorciones

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13 dic 2025, 07:00 UTC

Adquisiciones, fusiones, absorciones

A Chubb/AIG Deal Could Be Good for Shareholders and a Coup for Greenberg Family -- Barrons.com

13 dic 2025, 00:24 UTC

Adquisiciones, fusiones, absorciones

Want a Piece Of SpaceX? -- Barrons.com

12 dic 2025, 23:49 UTC

Adquisiciones, fusiones, absorciones

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

12 dic 2025, 22:52 UTC

Charlas de Mercado

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

12 dic 2025, 22:32 UTC

Ganancias

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12 dic 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

12 dic 2025, 20:45 UTC

Ganancias

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

12 dic 2025, 20:41 UTC

Charlas de Mercado

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

12 dic 2025, 20:20 UTC

Charlas de Mercado

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

12 dic 2025, 19:23 UTC

Ganancias

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

12 dic 2025, 18:35 UTC

Adquisiciones, fusiones, absorciones

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

12 dic 2025, 18:33 UTC

Adquisiciones, fusiones, absorciones

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

12 dic 2025, 18:31 UTC

Charlas de Mercado

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

12 dic 2025, 17:49 UTC

Ganancias

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

12 dic 2025, 17:34 UTC

Adquisiciones, fusiones, absorciones

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

Comparación entre iguales

Cambio de precio

Pharming Group NV previsión

Consenso

By TipRanks

0 ratings

Comprar

Mantener

Vender

De acuerdo con 0 analistas que ofrecen calificaciones bursátiles a para Pharming Group NV Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.